Adenovirus
10508
Respiratory infection
Adenoviruses are a large group of DNA viruses with a distinguished experimental history, including contributions to the discovery of RNA splicing and the elucidation of central pathways in cell transformation. Some adenoviruses are human pathogens. They are also very much in vogue as potential vaccine and gene therapy vectors. Structure-based redesign of their cell-targeting and antigenic properties is therefore a desirable goal (Harrison, 2010).
Baboon
Papio cynocephalus
9556
Bank vole
Clethrionomys glareolus
447135
Bear
Ursus americanus
9643
Birds
Passeroidea
175121
Brown Trout
Salmo trutta
8032
Buffalo
Bison bison
9901
Carnivores
Vulpes
9625
Cat
Felis catus
9685
Catfishes
Siluriformes
7995
Cattle
Bos taurus
9913
Chicken
Gallus gallus
9031
Chimpanzee
Pan troglodytes
9598
chinchillas
Chinchillidae
10150
Copper Pheasant
Syrmaticus soemmerringii
9067
Deer
Cervus elaphus
9860
Deer mouse
Peromyscus maniculatus
10042
Dog
Canis familiaris
9615
Ducks
Anas
8835
Ferret
Mustela putorius furo
9669
Fish
Hyperotreti
117565
Gerbil
Gerbillina
10045
Goat
Capra hircus
9925
Gray wolf
Canis lupus
9612
Guinea pig
Cavia porcellus
10141
Hamster
Mesocricetus auratus
10036
Horse
Equus caballus
9796
Human
Homo sapiens
9606
Macaque
Macaca fascicularis
9541
Mongolian Gerbil
Meriones unguiculatus
10047
Monkey
Platyrrhini
9479
Mouse
Mus musculus
10090
None
None
Parrot
Psittacidae
9224
Pig
Sus scrofa
9823
Rabbit
Oryctolagus cuniculus
9986
Rainbow trout
Oncorhynchus mykiss
8022
Rat
Rattus
10114
Raven
Corvus corax
56781
sei whale
Balaenoptera borealis
9768
Sheep
Ovis aries
9940
Squirrel
Spermophilus richardsonii
37591
Tree shrew
Tupaiidae
9393
Trouts, salmons & chars
Salmoninae
504568
Turkey
Meleagris gallopavo
9103
Vole
Microtus ochrogaster
79684
Water buffalo
Bubalus bubalis
391902
Adenovirus Type 3, 7, and 55 Vaccine rAdMHE3-55
Recombinant vector vaccine
Research
Plasmids pBRAd-MHE3 and pSKE3LR-h55 were each cloned by using ClonExpress Entry One Step Cloning Kit and then co-transfected into Top 10 cells. Through homologous recombination, Fragment h55 from pSKE3LR-h55 was integrated into pBRAd-MHE3, the resulting trivalent virus vector was named pBRAd-MHE3-h55. [Ref5892:Liu et al., 2018]
Intramuscular injection (i.m.)
A trivalent recombinant vector adenovirus vaccine composed of L3 epitopes from HAdV3, HAdV7, and HadV55. (Liu et al., 2018)
Intramuscular injection (i.m.)
HAdV3 hexon protein, HAdV7 hexon protein, HAdV55 hexon protein (Liu et al., 2018)
To verify the immunizing potential of the recombinant adenovirus rAdMHE3-h55, we immunized BALB/c mice with three doses of 5 X 10^9 VPs of rAdMHE3-h55. Sera were collected from the mice after the third immunization. Purified adenoviruses of HAdV-55, rAdMHE3, or rAdMHE3-h55 were subjected to western blot analyses with the mouse antisera. For all three adenoviruses, a hexon protein-like band of approximately 120 kDa were detected by anti-rAdMHE3-h55. ELISAs were used to further analyze the antisera from mice immunized with rAdMHE3-h55. The results showed that the mouseanti-rAdMHE3-h55 gave strong responses against HAdV-3, HAdV-7, HAdV-55 and rAdMHE3-h55. These findings confirmed that the recombinant adenovirus rAdMHE3-h55 was able to induce an immune response in mice and the antibodies possessed different neutralizing capabilities against HAdV-3, HAdV-7, and HAdV-55. (Liu et al., 2018)
Female BALB/c mice were divided into two groups: animals in group vaccinated received rAdMHE3-h55 vaccination, whereas animals in group unvaccinated were only infected with viruses without vaccination. Group vaccinated was further subdivided into the vaccination-challenge group and vaccination-unchallenged group, the latter was served as a control. Mice in group vaccinated were first vaccinated intramuscularly four times with 1X 10^10 genome copies of recombinant virus rAdMHE3-h55at 2-week intervals. (Liu et al., 2018)
In order to verify the protective effect of rAdMHE3-h55 vaccination, the respiratory system of the infected mice was examined because this was the target site of the HAdV infection. On post-challenge day 1, 3, or 5, mice were euthanized and their lung tissues were collected. Replication of HAdV-3, HAdV-7 and HAdV-55 in the lung tissues was detected by Q-PCR. There were statistically significant differences in the genome copies between vaccination-challenge group and un-vaccination group by day 5: HAdv-3 (p < 0.01, Mann- Whitney test), HAdV-7 (p < 0.05, Mann-Whitney test), HAdV-55 (p < 0.05, Mann-Whitney test). These data indicated that immunization of BALB/c mice with the recombinant trivalent virus AdMHE3-h55could protect animals simultaneously from infections byHAdV-3, HAdV-7, or HAdV-55.(Liu et al., 2018)
Two weeks after the fourth vaccination, mice in the vaccination-challenge group and unvaccinated group, with five or eight mice per time-point, were inoculated intranasally with 50 lL (about 2X 10^11 genome copies) of live HAdV-3, HAdV-7H, or AdV-55. Same number of naïve mice at each time point was served as negative control. Mice were euthanized on post-challenge day 1, 3, or 5.(Liu et al., 2018)
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Barr Labs, Inc.
VO_0000096
Live vaccine
Licensed
orally
United States
Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7, virus strains have not been attenuated. The vaccine is composed of two tablets (one of Adenovirus type 4 and one Adenovirus type 7) designed to pass intact through the stomach and release the live virus in the intestine (FDA: Adenovirus Vaccine).
Store refrigerated between 2° and 8° C (35° and 46° F). Do not freeze (FDA: Adenovirus Vaccine).
Virus is prepared in human-diploid fibroblast cell cultures (strain WI-38). The virus strains have not been attenuated. The virus is harvested and dried. The dry virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate and plasdone C (FDA: Adenovirus Vaccine).
orally
Baden et al., 2014
journal
Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH
First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)
2014
The Journal of infectious diseases
FDA: Adenovirus Vaccine
website
FDA: Adenovirus Vaccine
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm
Harrison, 2010
journal
Harrison SC
Virology. Looking inside adenovirus
2010
329
5995
1026-1027
Science (New York, N.Y.)
Kim et al., 2014
journal
Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A
Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model
2014
88
9
5100-5108
Journal of virology
Tompkins et al., 2007
journal
Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL
Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
2007
13
3
426-435
Emerging infectious diseases